Astellas Pharma Inc. ALPMF OTC · Healthcare · Japan
$16.55 +3.70% +$0.59
Summary
86 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 44% a year over the last 3 years.
- Out of every 100 JPY of revenue, 16 JPY is left as net profit.
- The share price is below the Bulios Fair Price.
- It earns 17 JPY a year on every 100 JPY of invested capital.
What to watch
- It missed profit estimates 4 times in the last 8 quarters.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.8 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 12% a year. For the next fiscal year analysts expect revenue to grow by 10%. Earnings per share grew by 44% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 25 JPY
- Research and development 14 JPY
- Sales and administration 37 JPY
- Taxes and other 7.2 JPY
- Net profit 16 JPY
Net profit, industry median (Drug Manufacturers - General) 14 JPY
Out of every 100 JPY of revenue, 16 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, safe- Yield
- 3.14%
- Paid out of profit
- 37%
- Raised in a row
- 3 years
You receive $0.50 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.